Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL : vimarsana.com

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

Related Keywords

China , , International Prognostic Index , China National Medical Products Administration , World Health Organization , Biomed Central , National Medical Products Administration , World Health , Dlbcl , Diffuse Largeb Cell Lymphoma , Hlx01 , Rituximab Biosimilar , R Chop , H Chop ,